Drug intelligence / Profile preview

iron-hes

Development stage: Unknown
Lead developer: Serumwerk Bernburg
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Administration: Intravenous, Parenteral

Overview

Iron-HES is an investigational intravenous iron preparation developed by Serumwerk Bernburg. It consists of iron complexed with hydroxyethyl starch (HES) as a carrier molecule. Designed as a parenteral iron formulation, it aims to replenish iron stores and treat iron-deficiency anemia, specifically in patients with chronic kidney disease (CKD). By supplying elemental iron, it supports the iron-deficiency pathway and erythropoiesis. It has been evaluated in Phase 2 clinical trials in Austria, comparing its safety and efficacy to iron dextran (Cosmofer).

Other names: iron-hydroxyethyl starchiron-hydroxyethyl starch complex

Beyond the preview

Go deeper on iron-hes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iron-hes.

Explore the full profile